Delivery Order SPE2DB22D9353-SPE2DB25FX2ET
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $37,209.60 to DMS Pharmaceutical Group Inc. for the supply of Xolair 300 mg/2 mL syringes. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. The delivery order is scheduled for completion by June 11, 2025, with performance taking place at the contractor's Park Ridge facility. This award was issued under...
- The Defense Logistics Agency awarded a delivery order valued at $18,568.80 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for Xolair 150 mg/1.2 mL powder vials. This firm fixed-price delivery order, awarded on September 3, 2025, with an ultimate completion date of September 24, 2025, contains no set-aside designation. The contract represents a discrete fulfillment under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. This $1,547.40 firm fixed-price delivery order was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on the open market despite its small business status. Xolair...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,605.50 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, and the contract carries no set-aside designation. The delivery order is scheduled for completion by September 24, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $1,547.40 for XOLAIR 75 mg/0.5 ml syringes. The award, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- The Defense Logistics Agency awarded a $4,642.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. The contract, issued on September 8, 2025, with an ultimate completion date of September 29, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $7,737.00 by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of October 6, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency awarded a $9,284.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 75 mg/0.5 mL syringes. The contract, issued on September 17, 2025, with an ultimate completion date of October 8, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at...
- The Defense Logistics Agency awarded a delivery order valued at $6,189.60 to DMS Pharmaceutical Group Inc. for XOLAIR 150 MG/ML syringes. This award, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will fulfill this order. XOLAIR (omalizumab) is a biologic...
- SPE2DB22D9353Indefinite Delivery Contract
- SPE2DB22D9353-SPE2DB25FX2ETDelivery Order
The Defense Logistics Agency awarded a $27,853.20 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. The contract, awarded September 17, 2025, with an ultimate completion date of October 8, 2025, carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499,999,999 through November 2026, which authorizes the agency to procure a comprehensive range of pharmaceutical products and medical supplies for Department of Defense healthcare facilities worldwide. Xolair (omalizumab) is a monoclonal antibody used primarily in the treatment of moderate-to-severe asthma and chronic idiopathic urticaria. As a critical supplier within the federal pharmaceutical supply chain since 2001, DMS Pharmaceutical Group leverages its woman-owned small business status to provide branded and generic prescription medications, biologics, and medical consumables to military health facilities. The company's established portfolio of DLA contracts demonstrates consistent capability in delivering specialized pharmaceutical products to support DoD healthcare operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $27.9k | 9/17/25 |